ID3 and cancer: Analysis of the Oncomine® database revealed that Id3 was significantly upregulated in 83 studies and downregulated in 84 studies in which cancers were compared to normal samples (threshold P = 0.05, fold change = 1.5, accessed date 18 June 2014).